ライフサイエンスコーパス: new drug

1 riteria governing regulatory approval of any new drug.

2 ents to facilitate clinical trial design for new drugs.

3 erculosis and provide additional targets for new drugs.

4 asis of their action and permitted design of new drugs.

5 biotics and rapidly evolves activity against new drugs.

6 ry with a view to targeting the pathway with new drugs.

7 knowledge, avenue for the rational design of new drugs.

8 re being recognized as potential targets for new drugs.

9 able impact on the successful development of new drugs.

10 um tuberculosis has prioritized the need for new drugs.

11 nt anthelmintics has prompted the search for new drugs.

12 past few years thanks to the introduction of new drugs.

13 latory mechanisms and support development of new drugs.

14 ed for significant delays in the approval of new drugs.

15 y WHO as a global priority for investment in new drugs.

16 innovative human platform for the testing of new drugs.

17 he bio-medical research and the discovery of new drugs.

18 as a major health issue fuelling demand for new drugs.

19 out dosing information as the only access to new drugs.

20 herapeutic strategies and the development of new drugs.

21 Of these, 65% are investigational new drugs, 17% are new drug applications and 18% are abb

22 Beyond continued research and development of new drugs, a focus on drug repurposing could alleviate t

23 long and costly pre-clinical testing in the new drug administration process.

24 Two novel approaches for the development of new drugs against AIDS are summarized each leading to th

25 ategy for drug repositioning, and identified new drugs against the VCP/p97/ERAD pathway in human dise

26 st cells is highly relevant to the design of new drugs aimed at eliminating HIV-1 from infected indiv

27 orm to predict the pharmaceutical effects of new drugs aiming to cure human atherosclerotic diseases.

28 s confidence in their use in Investigational New Drug and New Drug Application filings.

29 These findings provide new drug and vaccine targets and should help elucidate h

30 more frequent, requiring the development of new drugs and a better understanding of the targeted enz

31 Therefore, during the assessment of new drugs and candidate compounds, ROS generation is an

32 rns in FFS settings than the introduction of new drugs and clinical evidence as well as other factors

33 ion may be addressed, in part, by developing new drugs and devices/procedures to treat hypertension a

34 resistant isolates has prompted the need for new drugs and drug targets.

35 In this Compendium Review, we discuss new drugs and interventional treatments that are undergo

36 s era, including re-evaluating the impact of new drugs and mass drug administration.

37 Promoting Clinical Trials for Development of New Drugs and Medical Devices, Japan Agency for Medical

38 New drugs and regimens are being evaluated, and older dr

39 Several new drugs and regimens with promising activity against b

40 biotic resistance creates an urgent need for new drugs and targets.

41 Despite the upcoming availability of these new drugs and technologies that will add to existing typ

42 This has generally necessitated a switch to new drugs and the discontinuation of older ones, after w

43 s of disease and contribute to the design of new drugs and therapies.

44 the optimal management of NASH and approved new drugs and treatments, which urgently are needed.

45 tially useful for evaluating the efficacy of new drugs and ultimately for early-stage Alzheimer's dis

46 ion of a single drug, and the development of new drugs and vaccines depends on a better knowledge of

47 gondii biology and help us to better develop new drugs and vaccines.

48 ZIKV infection may be useful for testing of new drugs and vaccines.

49 lems include raising the bar for approval of new drugs and/or pricing of new agents based on the medi

50 VIVC Guidance, only very limited Abbreviated New Drug Application (ANDA) submission for ER oral drug

51 a A challenge study under an Investigational New Drug application (IND).

52 ng completion of phase III studies, eventual new drug application approval rates varied from 0% (zero

53 in their use in Investigational New Drug and New Drug Application filings.

54 ailable through an emergency Investigational New Drug application.

55 Abbreviated New Drug Applications (ANDA) data that included manufact

56 , 65% are investigational new drugs, 17% are new drug applications and 18% are abbreviated new drug a

57 a series of teleconferences; a review of 46 New Drug Applications from registration studies of uniqu

58 for several LMWH has expired and abbreviated new drug applications have been approved by the Food and

59 ew drug applications and 18% are abbreviated new drug applications, with the largest class of product

60 Drug Administration granted investigational new drug approval for the first phase 2A clinical trial

61 her with a significant drop in the number of new drug approvals raises the need for innovative approa

62 Monitoring of regulatory agencies for new drugs approvals ensures the resource is up-to-date.

63 Multiple new drugs are being developed to treat acute myeloid leu

64 e-threatening disease in many countries, and new drugs are clearly needed.

65 New drugs are crucially needed for children with cancer.

66 to widespread resistance to these therapies, new drugs are desperately needed to control the TB disea

67 Such a proposal is needed because new drugs are finally being tested in these rare "overla

68 previous analysis, approximately 70% of all new drugs are made up of only ring systems that have bee

69 New drugs are needed for each of these diseases.

70 on modification of NAFLD risk factors, many new drugs are now in clinical trials, including trials s

71 e due to developing parasite resistance, and new drugs are required that target the parasite in the l

72 New drugs are urgently needed for resistant strains, sho

73 Development of new drugs as well as investigation of drugs previously u

74 derable complexity to the rational design of new drugs, as it involves the optimization of multiple b

75 Methods: Conducted under an investigational new drug authorization, we prospectively enrolled patien

76 Conducted under an investigational new drug authorization, we prospectively enrolled patien

77 ntal and clinical evidence suggests that the new drugs bedaquiline (B) and pretomanid (Pa), combined

78 check an individual's response to potential new drugs before clinical trials.

79 The legal need for central approval of new drugs before manufacture has been in place continuou

80 erstand overall treatment effectiveness of a new drug being tested.

81 tion and histone modifications, with several new drugs being tested and some already approved by the

82 Alternative strategies with new drugs, both antiplatelet and anticoagulant agents, a

83 e Food and Drug Administration approval of 2 new drugs, both for the treatment of chronic heart failu

84 The current decrease of new drugs brought to the market has fostered renewed int

85 last two decades have produced only a single new drug but have represented a renaissance in our under

86 he bulk of its efforts on the development of new drugs, but an alternative approach is to improve the

87 compounds are central to the development of new drugs, but preparing them can be challenging because

88 that would include first the approval of the new drug by the regulatory agencies and second the intro

89 Here, we have tested a potent new drug called imipramine blue (IB), which is a chimeri

90 y cholangitis and PSC in the hope that these new drugs can be used more effectively.

91 distribution characterize VFV as a promising new drug candidate.

92 aving the way for testing its potential as a new drug candidate.

93 enges in malaria treatment, drug resistance, new drug candidates are urgently needed, which should pr

94 erties, Fynomer-Fc fusion proteins represent new drug candidates for the treatment of IL-17A mediated

95 Together, these data will help to develop new drug candidates that could lead to reversal of the F

96 y perceived as a large, untapped resource of new drug candidates, but so far it is unknown whether ta

97 -level that it is possible to avoid TDR to a new drug class for years.

98 Here, pioneers of this new drug class provide a bench-to-bedside review on prec

99 can promote the development of aptamers as a new drug class to block important oncological processes.

100 s temporarily reduced by the introduction of new drug classes and driven by nonresponding and treatme

101 ed by sharp decreases in the prevalence when new drug classes were introduced.

102 New drug classes, eg, inhibitors of vasopeptidases, aldo

103 lity criteria for commercial investigational new drug clinical trial applications submitted to the US

104 d to improved efficacy in clinical trials of new drug combinations, thereby increasing the survival o

105 worsening renal function (WRF) taking these new drugs compared with warfarin.

106 ecommends that in future, for the purpose of new drug compilations, NME is used for a new chemical dr

107 rug space each year and approximately 28% of new drugs contain a new ring system.

108 ug regimens that combine 2 or more expensive new drugs, continuous therapy, and the prolonged disease

109 The identified mechanism offers a new drug delivery platform into the ME.

110 New drug delivery systems are highly needed in research

111 argeting molecules other than VEGF and using new drug-delivery systems currently are being developed

112 ods to evaluate the therapeutic potential of new drugs, describe the development and evaluation of em

113 zed as one of the most important targets for new drug design in cancer, cardiovascular, and neurologi

114 ovides an effective pre-filtering method for new drug design.

115 ibility to others, could provide a basis for new drug development and treatment strategies.

116 New drug development has also been slow.

117 earch efforts will not only help to generate new drug development ideas and strategies, but also will

118 The lack of new drug development in kidney transplantation necessita

119 nt climate of pessimism about the absence of new drug development, it may be instructive to look back

120 stant tuberculosis, and provide an update on new drug development, results of several phase 2 and pha

121 ology and disease and also as a platform for new drug development.

122 e H inhibitors is an attractive strategy for new drug development.

123 ssential tools in the development process of new drugs, diagnostic procedures, and therapies.

124 We designed a new drug discovery approach that exploits both the stati

125 g and future pathway research may help focus new drug discovery efforts on key novel targets and mech

126 target individual proteins, has emerged as a new drug discovery paradigm.

127 ing starting points for the establishment of new drug discovery programs aimed at cancers harboring o

128 ctions, increasing support has been given to new drug discovery programs.

129 paration of libraries of novel compounds for new drug discovery programs.

130 ified HX, GSN and AAT as potential leads for new drug discovery programs.

131 tion patterns, leading to the development of new drug discovery tools.

132 crobial drug, host, and context; parallel to new drug discovery, broad ranging, multidisciplinary res

133 subject to animal testing upon adaptation in new drug discovery.

134 These findings suggest a continuous need for new drugs, early detection/treatment of HIV-1 infection.

135 uation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1,

136 harmacodynamic properties, with more than 40 new drugs entering the market in the last 15 years.

137 ome at a rapid pace, especially with several new drugs entering the market in the last few years.

138 researchers of his day, was given access to new drug entities, and the method he used to discover th

139 come a key element in the development of any new drug entity.

140 rd, informed consent, and an Investigational New Drug Exemption, six healthy volunteers and 10 patien

141 Many promising new drugs fail in the early stages of clinical trials.

142 Dimethyl fumarate (DMF), a new drug for multiple sclerosis (MS) treatment, acts aga

143 nterventions in chronic heart failure and of new drugs for acute heart failure.

144 g allergic reactions, representing potential new drugs for allergies.

145 ry tract microbiomes, and the development of new drugs for BV treatment.

146 timally utilize existing drugs or to develop new drugs for CNS disorders.

147 questions in lung biology and for developing new drugs for disorders such as cystic fibrosis and asth

148 these models a valuable tool for identifying new drugs for multifunctional drug therapy against acute

149 It is an urgent need to develop new drugs for Mycobacterium tuberculosis (Mtb), and the

150 The development of new drugs for the treatment of depression is strategic t

151 New drugs for the treatment of diabetes, glucagon-like p

152 y the US Food and Drug Administration of two new drugs for the treatment of idiopathic pulmonary fibr

153 New drugs for the treatment of tuberculosis (TB) are bec

154 e peptide-1 receptor agonists (GLP-1RAs) are new drugs for the treatment of type 2 diabetes.

155 r hybrid compounds show promise as potential new drugs for treating cerebral malaria.

156 st response, should lead to the discovery of new drugs for treating infections.

157 We aimed to evaluate a new drug-free fully bioresorbable lactic acid-based scaf

158 uture research may show benefit to patients, new drugs from older classes may show superior effective

159 ario Cancer Registry and Cancer Care Ontario New Drug Funding Program (CCO NDFP).

160 nships from DrugBank, and use it to discover new drug-gene relationships for both knowledge bases.

161 The exploratory investigational new drug guidance describes early phase 1 exploratory ap

162 Despite >100 clinical trials, only 2 new drugs had been approved by the US Food and Drug Admi

163 The cost of developing a new drug has increased sharply over the past years.

164 m treatment of bipolar disorder, but several new drugs have been assessed for this indication.

165 ost immunity towards tumor killing, and many new drugs have been developed to target this interaction

166 onduct and feasibility of phase 3 trials for new drugs have been proposed.

167 However, discovery and development of new drugs have been restricted because of differences in

168 re explored through case studies showing why new drugs have different periods of exclusivity in diffe

169 New drugs have not been forthcoming and are not likely t

170 need for effective IPF therapy, a number of new drugs have recently been, or are now being, evaluate

171 more than a decade, in the past 4 years five new drugs have shown efficacy with improvements in overa

172 HR ligands should be considered as potential new drugs in dermatology.

173 viding more rapid detection of resistance to new drugs in experimental regimens.

174 isons may provide insight into the effect of new drugs in patients with cytogenetic abnormalities.

175 In addition, there are insufficient new drugs in the pipeline to anticipate the appearance o

176 be used as a control arm in future trials of new drugs in this setting.

177 The key advantages of the new drug include a remarkably fast accumulation time (di

178 New drugs including N-acetylcysteine, bortezomib, recomb

179 ing studied clinically under investigational new drug (IND) applications submitted to the U.S. Food a

180 FMT must possess an approved investigational new drug (IND) permit to administer FMT for the purpose

181 the meetings, there were no investigational new drugs (INDs) in place for the candidate MCMs.

182 cal platform to help analyse the activity of new drugs (Innovative Therapy for Children with Cancer P

183 is in DA neuron VMAT vesicles and suggests a new drug interaction in which amphetamine induces CYAM d

184 y, simplification, anticipation of potential new drug interactions, pregnancy or plans for pregnancy,

185 nimal models and facilitating progression of new drugs into clinical trials.

186 ry process will speed up the introduction of new drugs into clinics.

187 Crucially this highlights how new drugs, introduced to circumvent known resistance mec

188 ll probably include add-on trials in which a new drug is combined with an intervention with establish

189 Designation of an NTE as a new drug is significant, as it may confer regulatory exc

190 odels, upon which preclinical development of new drugs is based, can only replicate host conditions w

191 This quintet of new drugs is likely to reshape the therapeutic landscape

192 and the potential of this intermediate as a new drug lead.

193 ompound can often determine the success of a new drug lead.

194 ibacterial resistance and the development of new drugs lead to a continuous change of guidelines for

195 er cells can identify thousands of potential new drug-leads.

196 screening campaign was carried out, seeking new drug-like compounds able to rescue DeltaF508-CFTR th

197 The spiraling cost of new drugs mandates a fundamentally different approach to

198 ife solutes is proposed, taking cubosomes as new drug nanocarriers of potential interest for drug del

199 To aid in the development of new drug nanocarriers, we propose a novel plasmonic nano

200 nd 3,4-methylenedioxypyrovalerone (MDPV) are new drugs of abuse that have gained worldwide popularity

201 The development of new drugs offers clinicians several choices to treat pat

202 hypothetical treatments that were labeled as new drug, old drug, or no drug.

203 ess during infection should help in devising new drugs or vaccines against hookworms.

204 dification of existing drugs, development of new drugs, or combination of novel drug delivery agents

205 perimentally measured the interaction of 123 new drug pairs, as a prospective validation set for our

206 In response to new drugs, pathogenic bacteria rapidly develop resistanc

207 formulation screening as a critical step for new drug product development, and how utilizing hydropho

208 BAT under an expanded-access Investigational New Drug program.

209 losis have focused on development of several new drug regimens and their evaluation in clinical trial

210 The development of new drug regimens that allow rapid, sterilizing treatmen

211 design of green catalysts and the pursuit of new drug regimens.

212 framework, PUDTI, is then designed to infer new drug repositioning candidates by integrating NDTISE,

213 The emergence of new drug resistance mutations declined dramatically from

214 accelerate eradication of infection, prevent new drug resistance, and prevent permanent lung injury.

215 ith fewer long-term liabilities, efficacy on new drug-resistant HIV-1 strains, and less frequent dosi

216 menced treatment for around 17% of estimated new drug-resistant patients.

217 All new drug-resistant viruses arise during intracellular re

218 ystem, identified about 58% of the estimated new drug-sensitive (DS) TB patients in 2016.

219 As a result, clinical trials of new drugs sometimes fail even after considerable success

220 ons were established to meet investigational new drug submission and institutional review board appro

221 enic compounds that could eventually lead to new drugs suitable for the treatment of some types of tu

222 y, these findings also suggest nNOSbeta as a new drug target and provide a new conceptual framework f

223 Hence, T-channels may be a promising new drug target for different cognitive deficits.

224 Our study identifies Vps34 as a new drug target for insulin resistance in Type-2 diabete

225 Together, CD30 is a promising new drug target for patients with CD30(+) advanced SM.

226 an pulmonary vascular homeostasis suggests a new drug target for the pharmacological management of pu

227 t-sensing receptor and represents a possible new drug target in metabolic disorders.

228 brain, as well as for identifying potential new drug target pathways.

229 in the N-terminal region of NHR trimer as a new drug target, and then we designed several short arti

230 se virus families and illuminate a potential new drug target.

231 grating heterogeneous information to predict new drug-target interactions and repurpose existing drug

232 ult, computational methods for predictioning new drug-target interactions have gained a tremendous in

233 Prediction of new drug-target interactions is critically important as

234 and (4) building DNILMF model and smoothing new drug/target predictions based on their neighbors.

235 cedure consists of four steps: (1) inferring new drug/target profiles and constructing profile kernel

236 tions of this channel and the development of new drugs targeting cellular proton transport.

237 modulation, and to support the discovery of new drugs targeting NRs.

238 a molecular basis for clinically developing new drugs targeting these gene mutations for GIST therap

239 high-risk women and may lead to discovery of new drug targets against associated adverse pregnancy ou

240 nction, which is significant for identifying new drug targets and developing new therapeutic approach

241 New drug targets and lead compounds exempt from cross-re

242 ly needed as more relevant tools to identify new drug targets and therapies.

243 drome (MetS) has led to the realisation that new drug targets are needed to either reduce obesity or

244 al biology in PD risk, and suggest potential new drug targets for PD.

245 lasmic gelsolin signaling pathway, providing new drug targets for the treatment of demyelination dise

246 eria bancrofti, and Brugia malayi available, new drug targets have been identified.

247 refore, there is an imperative to search for new drug targets in S. haematobium and other schistosome

248 rapid development of HIV-1 drug resistance, new drug targets need to be explored continuously.

249 These key drivers provide new drug targets to improve the sensitivity of cancer th

250 L1-interacting molecules that could serve as new drug targets to treat APOL1-associated renal disease

251 be used to improve existing drugs, identify new drug targets, and understand the basis of drug resis

252 anscriptional regulators and have emerged as new drug targets, but their functional distinction has r

253 esis represents a useful strategy to uncover new drug targets.

254 f cancer diagnosis and the identification of new drug targets.

255 subgroups and lead to the identification of new drug targets.

256 The development of new drugs that are designed to be more selective inducer

257 rder are limited in their effectiveness, and new drugs that can easily be translated into the clinic

258 therefore has been proposed as a target for new drugs that control KRAS transcription, which require

259 effective drugs, and to continue to develop new drugs that do not cause these side-effects and have

260 urn will have a greater chance of validating new drugs that may be effective for the disease.

261 Developing new drugs that specifically target SUMOylation offers a

262 derable progress has been made in developing new drugs that target additional MC/B mediators or recep

263 Next to the development of new drugs, the strategy of combining agents with synergi

264 ort translational pharmacological studies of new drug therapies and provide evidence for engagement o

265 of resistance and the restricted pipeline of new drug therapies pose considerable risks to global hea

266 10 fusion protein as a long-needed potential new drug to stop persistent pain states.

267 Thus, arglabin may represent a promising new drug to treat inflammation and atherosclerosis.

268 is currently in preclinical development as a new drug to treat lung infections caused by Gram-negativ

269 optosis may contribute to the development of new drug to treat lymphomas and oncovirus infections.

270 a validated target for the identification of new drugs to be added to the combination regimen recentl

271 esis and pave the way for the development of new drugs to hamper the clinical effects of the disease.

272 g marketing approval and the availability of new drugs to patients.

273 bsequently may facilitate the development of new drugs to silence the oncogenic effect of SET/TAF-Ibe

274 these hurdles and, potentially, to bringing new drugs to the clinic more quickly and efficiently.

275 noketone derivatives as means of identifying new drugs to treat Chagas disease in the acute phase wit

276 In 2014, several new drugs to treat hepatitic C virus received US Food an

277 compliance or tolerance of this medication, new drugs to treat hypertension are urgently needed.

278 resistance, necessitates the development of new drugs to treat influenza infections.

279 There is an urgent need for new drugs to treat malaria, with broad therapeutic poten

280 However, as we acknowledge the need for new drugs to treat these desperately ill patients, there

281 tly increased only in the presence of recent new drug treatment with antiepileptics or allopurinol, r

282 With a clear clinical need for new drug treatments for HAT that address both the hemoly

283 New drug treatments, clinical trials, and standards of q

284 ilitating the mechanism-based development of new drug treatments.

285 complexes with proteins that are targets of new drugs under development defines the future of epigen

286 SJS/TEN mostly manifest as a reaction to new drug use, but little is known about their incidence

287 nhibitors that might be further optimized to new drugs useful for the treatment of Parkinson's diseas

288 that an accelerated approval of a particular new drug using an intermediate end point, such as MRD, w

289 la melanogaster may enhance the detection of new drugs via modifier or 'enhancer/suppressor' screens,

290 arm, as expected with the introduction of a new drug vs remaining on a well-tolerated drug.

291 In a large clinical trial, this new drug was found to reduce hospitalization and mortali

292 fter a gap of more than 10 years in which no new drugs were approved.

293 development for testing the interactions of new drugs with DNA before the drug efficacy can be asses

294 dynamics can be a powerful tool in designing new drugs with engineered binding/unbinding kinetics.

295 rgoing a renaissance with the expectation of new drugs with enhanced levels of efficacy and safety.

296 New drugs with novel mechanisms of action, such as cardi

297 only be resolved through the development of new drugs with novel mechanisms of action.

298 herefore represent opportunities to discover new drugs with unique mechanisms of action.

299 The incorporation of such new drugs within a CHOP backbone is under investigation

300 fected persons in the United States with the new drugs would cost an additional $65 billion in the ne